ST. LOUIS, Aug. 21, 2025 /PRNewswire/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel immune-stimulating drugs to augment routine tumor destruction techniques, announced the completion of its multicenter clinical trial (SAKK 66/17) conducted in collaboration with the Swiss Cancer Institute (formerly known as SAKK). This milestone — along with completion of the Company's INJECTABL-1 trial covering different indications, which the Company announced in July 2025 — marks a significant advancement in evaluating the immunologically mediated anticancer effects of intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors.

The SAKK 66/17 trial was designed to assess the safety and tolerability of IP-001 in combination with thermal ablation in patients with various types of advanced solid tumors, with a second phase assessing efficacy for melanoma and soft-tissue sarcoma. With treatment completed for all patients in both phases, data analysis is now underway.

Prof. Dr. Markus Joerger, Principal Investigator for the study at the Cantonal Hospital St. Gallen Clinic for Medical Oncology and Hematology commented: "This collaboration between Immunophotonics and Swiss Cancer Institute highlights the importance of partnerships in advancing cancer treatments. With the completion of this trial, we made the next important step in the development of a new treatment option for patients with advanced solid tumors. The results could have a meaningful impact in the fight against cancer."

The results of this trial provide further evidence regarding safety and efficacy of IP-001 in a broader patient population. Immunophotonics and Swiss Cancer Institute remain committed to advancing the development of this potential cancer treatment and bringing it to patients in need.

About IP-001

IP-001 is a proprietary glycan polymer that generates tumor antigen depots and acts as a potent, multimodal immune stimulant intended to induce immunological responses to eradicate cancer. IP-001 is designed to (1) prolong the availability of the targeted tumor antigens, (2) facilitate the recruitment and activation of innate immune cells such as antigen-presenting cells (APCs), (3) increase the uptake of the tumor antigens into the APCs, and (4) lead to a downstream adaptive immune response against the tumor cells. Activation of a systemic, adaptive immune response allows immune effector cells to seek out and eliminate tumor cells throughout the body.

About Immunophotonics

Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology^®. IP-001, which is the first asset from the company's intellectual property platform and is currently assessed in multiple clinical trials, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific immune response in solid cancers. By combining routine energy therapies, such as ablation or radiation, with injection of its proprietary immunoadjuvant (IP-001), Immunophotonics aims to trigger a systemically active anti-cancer immune response that can destroy circulating tumor cells and micrometastases left behind after ablation. The company's world headquarters is in St. Louis, Missouri, USA, and its European headquarters is in Bern, Switzerland. For more information, visit www.immunophotonics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements. Such statements involve inherent risks and uncertainties, and numerous factors could cause actual results to differ materially from those made or implied herein. All information provided in this press release is as of the date of this press release, and Immunophotonics, Inc. undertakes no duty to update such information, except as required under applicable law.

Investor Contacts:

Contact:

IR@immunophotonics.com

Related Links:

https://www.immunophotonics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunophotonics-and-swiss-cancer-institute-complete-sakk-6617-phase-1b2a-multicenter-clinical-trial-for-treatment-of-solid-tumors-302535183.html

SOURCE Immunophotonics, Inc.